



Lymphangi leiomyomatosis and pregnancy: a mini-review

Jieshu Zhou^{1,2} · Min Diao^{1,2}

Received: 4 January 2024 / Accepted: 10 March 2024 / Published online: 9 April 2024
© The Author(s) 2024

Abstract

Lymphangi leiomyomatosis (LAM) is a slow progressive, rare cystic lung disease in women of reproductive age, associated with infiltration of the lung by atypical smooth muscle like cells, leading to the cystic destruction of the lung parenchyma. As LAM exclusively affects women of childbearing age, it can arise or exacerbate during pregnancy. Many patients with LAM are discouraged from pregnancy, although there is not much objective evidence effect on fertility. Patients diagnosed with LAM during pregnancy experience worse outcomes, so the safety of pregnancy is a vexing problem. What was worse, treatment strategies are limited on the effects of LAM on pregnancy outcomes. Pregnancy could be considered in LAM patients. Successful delivery in women with LAM depends on the condition of the LAM, which is in turn dependent on obstetricians and respiratory physicians. In this review, we describe the epidemiology, pathogenesis, diagnosis, clinical features and the treatment strategies of LAM during pregnancy.

Keywords Lymphangi leiomyomatosis · Pregnancy · Maternal health · Pulmonary function · mTOR

Abbreviations

LAM	Lymphangi leiomyomatosis
mTOR	Mammalian target of rapamycin
ERS	European Respiratory Society
S-LAM	Sporadic lymphangi leiomyomatosis
TSC-LAM	Tuberous sclerosis complex lymphangi leiomyomatosis
TSC	Tuberous sclerosis complex
AMLs	Angiomyolipomas
VEGF-D	Vascular endothelial growth factor-D
GnRH	Gonadotrophin-releasing hormone
FEV1	Forced expiratory volume in one second
DLCO	Diffusion in the lung of carbon monoxide
FVC	Forced vital capacity
MMPs	Matrix metalloproteinases

Background

Lymphangi leiomyomatosis (LAM) is a slow progressive, rare, multisystemic disease associated with cystic lung and abdominal tumors and chylous fluid due to abnormal proliferation and infiltration of smooth muscle cells, called LAM cells [1]. LAM cells are caused by mutations in the tuberous sclerosis complex genes (*TSC1/TSC2*) that result in activation of the mammalian target of rapamycin (mTOR), which regulates cellular growth and proliferation [2]. Progressive dyspnea and spontaneous pneumothorax are the most common clinical symptoms of LAM, especially in pregnant women [3]. Mounting evidence suggests that this disease exclusively affects women and exacerbates pregnancy and estrogen use [4, 5]. Notably, the European Respiratory Society (ERS) guidelines mention that pregnancy is associated with increased LAM complications [6]. Many patients with LAM avoid or are discouraged from pregnancy [7], although there is not much objective evidence. In this review, we describe the epidemiology, pathogenesis, diagnosis, and clinical features of LAM during pregnancy and highlight the treatment strategies. We aimed to explore the characteristics of LAM during pregnancy and provide evidence for a good outcome of pregnancy and maternal health.

✉ Min Diao
1988228cd@163.com

¹ Department of Anesthesiology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China

² Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, Sichuan, China

Epidemiology during pregnancy

LAM can occur sporadically (S-LAM) or accompany with tuberous sclerosis complex (TSC) (TSC-LAM). S-LAM is a rare disease restricted to premenopausal women. The prevalence of S-LAM was 4.9 per million women (range, 3.4–7.8 per million women) [8]. TSC-LAM has a high prevalence in women (range, 1–20 per million women), which increases with age [9]. It is about 30–40% TSC women has LAM [10]; however, TSC has no sex bias. Although TSC-LAM appears to be more common, mostly pregnant women with LAM for medical evaluation have sporadic LAM [11]. This paradox remains unexplained but may be ascribe to the lack of sex bias of TSC or because the prevalence of TSC-LAM is higher in older than in younger women. The average age at the diagnosis of S-LAM is 34 years [12]. In a retrospective study of pregnancy in patients with LAM, two-thirds of the patients were pregnant [13]. However, pregnancy is rare once the diagnosis is made. There are few firm data on the prevalence of LAM during pregnancy.

Pathogenesis of LAM

Both TSC-LAM and S-LAM are caused by mutations in the tumor suppressor complex genes *TSC1* and *TSC2* which has been present in lung LAM cells [14]. *TSC1* and *TSC2* are negative regulators of mammalian target of rapamycin (mTOR), which regulates cellular growth and proliferation. Overactivation of the mTOR pathway in TSC-mutant cells results in LAM cell growth and proliferation [15]. Therefore, mTOR inhibition has been used as the main therapeutic strategy for LAM.

The source of LAM cells remains unknown; however, LAM lesions have been reported in the uterus [16, 17], and *TSC2* gene mutations have been observed in the uterus and lungs of patients with S-LAM [18]. S-LAM has the stronger sex preference. Lung tissues from LAM patients were found to express high levels of both estrogen and progesterone receptors [19], which suggests the hormonal sensitivity of this disease. Estrogen may play a pivotal role in S-LAM, supported by the higher occurrence of the disease in women of reproductive age and the fact the complications of LAM in pregnancy are 11 times higher than at other times [20]. In vitro studies showed that estrogen induces growth of cultured *TSC2*-deficient cells and tumor cells derived from patients with LAM through pyruvate kinase M2 [21]. Gu et al. [22]. reported that estrogen-ERK2 pathway activated mTOR pathway by enhancing the effect of late response-gene *Fra1*. Oberstein et al. [23]

also suggested that oral contraceptive pills, which contain high levels of estrogen, serve as catalysts to promote the occurrence of LAM. The female sex hormone environment has been implicated in the pathogenesis of LAM. Progesterone as another sex hormone is plays a key role in pregnancy maintenance. Progesterone was found to increase the migration and invasion of *TSC2*-deficient cells [24], and previous report also revealed that administration of progesterone with oophorectomy is the most effective therapeutic for LAM. However, the quality of evidence regarding hormone therapy is low.

Presentation and clinical features during pregnancy

Lung

The major pulmonary symptoms of LAM include dyspnea on exertion, pneumothorax, and chylothorax. Some patients have mild pulmonary symptoms 2–3 years before diagnosis, and the symptoms worsen during pregnancy [25]. Progressive dyspnea is usually the first symptom when LAM is diagnosed during pregnancy. Dyspnea is easily masked by other diagnoses such as chronic obstructive pulmonary disease and asthma; therefore, the diagnosis of LAM is often delayed [26]. Khaddour et al. [27] reported that a female with history of G3P2A1 presented with the chief complaint of worsening dyspnea, which was misdiagnosed as asthma during pregnancy. Progressive dyspnea may be caused by LAM cell destruction in the lung parenchyma and decreased lung function.

Spontaneous pneumothorax is a classic presentation of LAM with pregnancy. Over one-third of patients experience pneumothorax and about two-thirds experience recurrence of pneumothorax during pregnancy [26]. Chylothorax is a clinical manifestation in about 20% of LAM patients. The incidence of pneumothorax and chylothorax during pregnancy was 11 times higher than that at other times [20]. Pleurodesis is recommended for spontaneous pneumothorax, which can reduce the risk of pneumothorax recurrence [28]. However, chemical pleurodesis may cause maternal and fetal hepatic toxicity [29]. Thoracic drainage (intercostal drainage) is often used in patients with pneumothorax during pregnancy and is associated with reduced dyspnea [30]. In retrospective research shown that air travel increases the incidence of pneumothorax in patients with LAM, especially in those with larger cysts and lower lung function. The incidence of pneumothorax in LAM after air travel is approximately 1000 times higher than general women and is about threefold higher than baseline incidence [31]. However, current guidelines do not restrict patients with LAM from air travel [6]. We believe that the advice to avoid air

travel should be adopted during pregnancy, because pregnant patients are at high risk of pneumothorax and reducing unnecessary air travel can reduce the incidence of pneumothorax and other lung complications.

Extrapulmonary presentations

Extrapulmonary presentations, including renal angiomyolipomas (AMLs) and lymph node enlargement, are reported in some cases of pregnancy. Angiomyolipomas (AMLs) are benign tumors usually localized in the kidneys and occur in almost 90% of patients with TSC-LAMs and in approximately 30–40% of patients with S-LAM [26, 32]. AMLs usually present with abdominal pain, hypotension, and shock due to bleeding or rupture [33]. Rapid growth of AMLs has been reported in pregnant patients [34–36], which will lead to increase the rate of AMLs rupture. AMLs are atypical presentations of LAM; however, in some case reports of pregnancy complicated by LAM, the first symptoms experienced by most patients were abdominal pain and renal hemorrhage. The treatment for AMLs is arterial embolization, nephrectomy, cryoablation, and radiofrequency ablation. When tumors are less than 5 cm in size, cryoablation and radiofrequency ablation are the treatments of choice for most AMLs. When nephrectomy is not possible, embolization is considered the primary treatment. There is no confirmed effect of radiation on the baby if embolization is performed during pregnancy with AMLs (Table 1).

Diagnosis and evaluation

High-resolution computed tomography (HRCT)

Diffuse thin-walled cysts in the lung parenchyma are the most remarkable feature of LAM on high-resolution computed tomography scans. Although the characteristic cystic disease on CT alone has a sensitivity and specificity for the diagnosis of LAM is about 90%, it is considered insufficient to diagnose LAM [37]. Diagnosis of LAM requires exclusion of other causes of diffuse cystic lung diseases, such as chronic obstructive pulmonary disease,

Langerhans cell histiocytosis, and cyst-forming metastatic lung tumors [25].

VEGF-D and pulmonary function

Serum vascular endothelial growth factor-D (VEGF-D) testing has been suggested as a noninvasive method to confirm the diagnosis of LAM [6, 37, 38]. An elevated serum VEGF-D level >800 pg/mL has a sensitivity of 73% and a specificity of 100% and provides a definite diagnosis of LAM in patients with a clinical symptoms and characteristic chest high-resolution computed tomography result [6]. Serum VEGF-D testing reduces the need for invasive lung biopsy in patients with LAM, which can be used in the diagnosis of pregnancy complicated with LAM. Hirose et al. [39]. showed that the serum level of VEGF-D remains unchanged during pregnancy with LAM, suggesting that estrogen has little effect on serum VEGF-D levels. VEGF-D is able to predict the severity of the disease, and baseline serum VEGF-D levels are negatively correlated with pulmonary function testing [33, 40]. Both VEGF-D and pulmonary function testing can be used to assess disease progression. Pulmonary function tests mostly revealed an airflow obstructive impairment pattern or reduced pulmonary diffusion capacity in patients with LAM [41]. Pulmonary function testing of forced expiratory volume in one second (FEV1) has shown the strongest correlation with LAM, and the rate of decline in FEV1 has been variably reported as 75–135 mL per year in patients with LAM [42]. Pulmonary function testing is the most effective and non-invasive method for assessing the severity and progression of lung disease in LAM [43]. A lower baseline pulmonary function level is associated with high mortality in LAM. Most pregnancies in women with LAM are associated with acceleration of lung function decline [44]. Angelo et al. [45] performed a retrospective study of 16 LAM pregnant patients and showed that the percentage of predicted FEV1 and diffusion in the lung of carbon monoxide (DLCO) were lower than those before pregnancy. Therefore, we concluded that pregnant LAM patients have poorer Pulmonary function with lower FEV1, forced vital capacity (FVC), and DLCO. Time-course monitoring of pulmonary function during pregnancy is vital to assessing LAM progression.

Table 1 Clinical features and treatment during pregnancy

Organ	Manifestation	Treatment
Lung	Dyspnea	Oxygen therapy
	Pneumothorax	Pleurodesis
	Chylothorax	Thoracic drainage
Renal	Abdominal pain	Arterial embolization
	Bleeding or rupture	Nephrectomy
		Cryoablation
		Radiofrequency ablation

Biopsy

Biopsy is the gold standard for diagnosing LAM. The lung biopsy can be performed through transbronchial or video-assisted thoracic surgery when the diagnosis cannot be made noninvasively in LAM patients [46].

Treatment during pregnancy

mTOR inhibitors

The American Thoracic Society and Japanese Respiratory Society Guidelines recommend sirolimus as a first line treatment for LAM because it improves lung function and reduces serum VEGF-D levels by inhibiting the mTOR pathway. The Multicenter International LAM Efficacy of Sirolimus (MILES) trial showed that sirolimus treatment improves FVC and FEV1 in patients with LAM and moderate lung impairment [47]. With respect to effective dosing, sirolimus was administered at 2 mg/d, and the blood concentration was maintained at 5–15 µg/L. Regrettably, sirolimus is a risk category C for pregnancy, and guidelines advise discontinuing it 12 weeks before pregnancy. Sirolimus is also an effective treatment for LAM while the therapy continues, but disease progression resumes once treatment is discontinued [25]. Sirolimus has not been used in pregnant LAM patients, except in some case reports. Shan et al. [11] reported that sirolimus increased the risk of spontaneous abortion and premature delivery during pregnancy. In some unintended pregnancy cases and retrospective data, the use of the drug before or during pregnancy did not increase adverse neonatal outcomes (Table 2), and the use of small doses (1–2 mg/d) can stabilize lung function in pregnant women. Faehling et al. [48, 49] reported the case of a patient with long-term LAM administered sirolimus who had a second successful pregnancy. They believe that low blood levels of sirolimus (3–5 µg/L) may be safe in pregnant LAM patients, which is in line with previous reports on treatment with low-dose sirolimus (< 5 µg /mL) being effective in stabilizing lung function. However, there is little evidence of sirolimus use in pregnancy with LAM. The safety and efficacy of sirolimus in pregnancy requires robust research data in the long term.

Recent studies on mTOR signaling have suggested the use of other drugs, such as biguanides [50], statins [51], and doxycycline [52]. Given the favorable safety features of biguanide in pregnancy, it might be a good alternative treatment option for pregnant LAM patients [53, 54]. An ongoing clinical trial investigating the safety and efficacy of statins and mTOR inhibitors in patients with LAM has completed enrolment; however, the safety of statins during pregnancy remains questionable. Matrix metalloproteinases (MMPs) may contribute to cyst formation in patients with LAM. Treatment with doxycycline, an inhibitor of MMPs, has been investigated in this regard. The case report suggests a potential benefit of doxycycline therapy for patients with LAM [24], and lung tissues obtained from patients with LAM were found to express

Table 2 Patients with LAM and a history of pregnancy after taking sirolimus

patient	Type of LAM	Age of diagnosis(years)	Duration of taking sirolimus (month)	Dose (mg)	Serum level (ug/L)	Time of discontinuation (weeks)	Age of pregnancy(years)	Mode of delivery	Gesta-tional weeks	Complication of LAM	Obstetric diseases	infants
1	S-LAM	29	53	1.5	7.8	At pregnancy 8weeks	34	CS	37	None	None	Healthy
2	S-LAM	30	46	1.5	7	At pregnancy 5weeks	34	CS	35	Rupture of AMLs	None	Healthy
3	S-LAM	25	70	1	NA	At pregnancy 4weeks	35	CS	38	None	None	Healthy
4	S-LAM	34	29	1	6	Before pregnancy 27weeks	37	VD	39	None	None	Healthy
5	S-LAM	26	12	1	NA	Before pregnancy 8weeks	27	VD	38	PX	None	Healthy
6	S-LAM	30	6	1	NA	Before pregnancy 12weeks	33	CS	37	PX	None	Healthy
9	S-LAM	23	30	NA	NA	At pregnancy	39.8	CS	40	None	None	Healthy
10	NA	25	9	2	2	At pregnancy 7–23 weeks	29	CS	32	PX	None	Healthy
11	NA	25	61	2	03-May	no	34	CS	32	None	None	Healthy

S-LAM sporadic lymphangioleiomyomatosis, TSC tuberous sclerosis complex, AMLs angiomylipomas, PX pneumothorax, CS cesarean section, VD vaginal delivery

high concentrations of MMPS-2 and MMPS-9 [55]. Doxycycline is effective for the treatment of LAM [56], but the use of doxycycline during pregnancy has historically been discouraged due to potential adverse effects on the fetal teeth during 16 weeks postconception. Although a study assessed doxycycline use during pregnancy [57], the data are insufficient to state that there is no risk. So clinical trial guidelines do not suggest the use of doxycycline as a treatment for LAM because there are no beneficial effects in LAM patients who already have lung function impairment. The use of doxycycline for treatment of LAM during pregnancy has not been reported yet.

Hormone treatment

Pregnancy and LAM are inseparable. Although hormone-related treatments, such as oophorectomy and estrogen, progesterone, and GnRH treatments, may have potential against LAM, pregnancy does not allow hormonal manipulation using progesterone, estrogen antagonists, or luteinizing hormone-releasing hormone agonists. There is a lack of robust clinical randomized double-blinded placebo-controlled trial studies on the management of LAM in pregnancy using sex hormonal agents. Oprescu et al. [58] showed that hormonal treatment was linked to an increased risk of death in patients with LAM. Therefore, therapeutic strategies using female sex hormones have not been successful and are, therefore, not recommended by the guidelines.

Other pharmacological agents

Reversible airway obstruction occurred in 20% of patients with LAM and association with prognosis [59]. Bronchodilator drugs are used in patients with asthma-like symptoms caused by LAM. Activation of protein kinase A (PKA) by treatment with β -agonists increased S6 phosphorylation level independent of mTOR [60]. Retrospective data from LAM patients showed that a combination of bronchodilators with sirolimus is better than sirolimus alone for stabilization of pulmonary function.

To date, there are only few effective pharmacological treatments for pregnant LAM patients, and the benefits of available medications during pregnancy are debatable owing to side effects on the fetus. Treatment of LAM in pregnancy, therefore, focuses on symptom management and prevention of complications.

Lung transplantation

Lung transplantation is the last treatment strategy for patients with worsened lung function at the end stage. Lung transplantation is an effective treatment that could improve the quality of life of patients with LAM [61, 62]. In a 2021

analysis, Ji Zhang et al. [63] evaluated 25 patients with LAM who underwent lung transplantation in China between 2010 and 2018 and found that 19 (76%) patients had a history of pregnancy and six (24%) patients had a recent history of pregnancy. However, this article does not show relationship between lung transplantation and pregnancy.

Effect of pregnancy on LAM

Pregnancy is an important issue for patients diagnosed with LAM. In a registry study of 230 patients with LAM, two-thirds of the patients had a history of pregnancy. According to Cohen et al. [13], 78.8% of the patients had favorable pregnancy outcomes before LAM diagnosis. LAM diagnosis during pregnancy was related to a higher incidence of complications, such as recurrent pneumothorax [20], rupture of renal AMLs [64], and loss of pulmonary function [45].

Effect of LAM on pregnancy

Patients with LAM have more premature births and miscarriages than those without LAM. In line with these reports, miscarriage was associated with less fertile LAM patients [65]. In terms of delivery methods, a retrospective study showed that 75% (12/16) of the patients underwent cesarean section, and only 25% of the patients gave birth naturally. A high rate of cesarean sections was observed owing to the reduced risk of rupture of AMLs and pneumothorax during labor. The timing of termination of pregnancy is mainly based on the condition of the diseases progression. Pregnancy may adversely affect the prognosis of patients with LAM; however, it was not associated with their survival.

Conclusion

Pregnancy is a vexing problem for reproduction women owing to reduced fertility, increased risk of miscarriage, premature delivery, and complications of LAM. Successful delivery in women with LAM depends on the condition of the LAM, which is in turn dependent on obstetricians and respiratory physicians. Pregnancy could be considered in LAM patients, pregnancy plans should be made according to individual conditions, and pulmonary function should be monitored in real time during pregnancy. Future research should explore strategies to avoid complications and improve pulmonary function, such as use of drugs in pregnant women and physical exercise.

Author contributions JSZ: manuscript writing and revision. DM: project development, manuscript revision and review. All authors read and approved the final manuscript.

Funding The authors have not disclosed any funding.

Declarations

Conflict of interest The authors have not disclosed any competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Johnson SR (2006) Lymphangioleiomyomatosis. *Eur Respir J* 27(5):1056–1065
- Henske EP, McCormack FX (2012) Lymphangioleiomyomatosis - a wolf in sheep's clothing. *J Clin Invest* 122(11):3807–3816
- McCormack FX (2008) Lymphangioleiomyomatosis: a clinical update. *Chest* 133(2):507–516
- Brunelli A, Catalini G, Fianchini A (1996) Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. *Int J Gynaecol Obstet* 52(3):289–290
- Johnson SR, Tattersfield AE (1999) Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. *Am J Respir Crit Care Med* 160(2):628–633
- McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH et al (2016) Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. *Am J Respir Crit Care Med* 194(6):748–761
- Lara B, Fornet I, Goya M, López F, De Miguel JR, Molina M, Morales P, Quintana E, Salicrú S, Suárez E et al (2012) Contraception, pregnancy and rare respiratory diseases. *Arch Bronconeumol* 48(10):372–378
- Harknett EC, Chang WY, Byrnes S, Johnson J, Lazor R, Cohen MM, Gray B, Geiling S, Telford H, Tattersfield AE et al (2011) Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. *QJM* 104(11):971–979
- Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ, Franz DN, McCormack FX, Young LR (2013) Lymphangioleiomyomatosis screening in women with tuberous sclerosis. *Chest* 144(2):578–585
- Crino PB, Nathanson KL, Henske EP (2006) The tuberous sclerosis complex. *N Engl J Med* 355(13):1345–1356
- Shen L, Xu W, Gao J, Wang J, Huang J, Wang Y, He Y, Yang Y, Tian X, Xu KF (2021) Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM). *Orphanet J Rare Dis* 16(1):133
- Tomasian A, Greenberg MS, Rumerman H (1982) Tamoxifen for lymphangioleiomyomatosis. *N Engl J Med* 306(12):745–746
- Cohen MM, Freyer AM, Johnson SR (2009) Pregnancy experiences among women with lymphangioleiomyomatosis. *Respir Med* 103(5):766–772
- Kristof AS (2010) mTOR signaling in lymphangioleiomyomatosis. *Lymphat Res Biol* 8(1):33–42
- Yu J, Henske EP (2010) mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the “perfect storm” of prometastatic factors in LAM pathogenesis. *Lymphat Res Biol* 8(1):43–49
- Hayashi T, Kumasaka T, Mitani K, Terao Y, Watanabe M, Oide T, Nakatani Y, Hebisawa A, Konno R, Takahashi K et al (2011) Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients. *Am J Surg Pathol* 35(12):1776–1785
- Prizant H, Sen A, Light A, Cho SN, DeMayo FJ, Lydon JP, Hammes SR (2013) Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs. *Mol Endocrinol* 27(9):1403–1414
- Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. *Proc Natl Acad Sci U S A* 97(11):6085–6090
- Gao L, Yue MM, Davis J, Hyjek E, Schuger L (2014) In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. *Virchows Arch* 464(4):495–503
- Johnson SR, Tattersfield AE (2000) Clinical experience of lymphangioleiomyomatosis in the UK. *Thorax* 55(12):1052–1057
- Lu Y, Liu X, Zhang E, Kopras EJ, Smith EP, Astreinidis A, Li C, Leung YK, Ho SM, Yu JJ (2020) Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells. *PLoS ONE* 15(2):e0228894
- Gu X, Yu JJ, Ilter D, Blenis N, Henske EP, Blenis J (2013) Integration of mTOR and estrogen-ERK2 signaling in lymphangioleiomyomatosis pathogenesis. *Proc Natl Acad Sci U S A* 110(37):14960–14965
- Oberstein EM, Fleming LE, Gómez-Marin O, Glassberg MK (2003) Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and the onset of disease. *J Womens Health (Larchmt)* 12(1):81–85
- Sun Y, Gu X, Zhang E, Park MA, Pereira AM, Wang S, Morrison T, Li C, Blenis J, Gerbaudo VH et al (2014) Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells. *Cell Death Dis* 5(5):e1231
- McCarthy C, Gupta N, Johnson SR, Yu JJ, McCormack FX (2021) Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. *Lancet Respir Med* 9(11):1313–1327
- Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR et al (2006) The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. *Am J Respir Crit Care Med* 173(1):105–111
- Khaddour K, Shayuk M, Ludhwani D, Gowda S, Ward WL (2019) Pregnancy unmasking symptoms of undiagnosed lymphangioleiomyomatosis: Case report and review of literature. *Respir Med Case Rep* 26:63–67
- Almoosa KF, Ryu JH, Mendez J, Huggins JT, Young LR, Sullivan EJ, Maurer J, McCormack FX, Sahn SA (2006) Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. *Chest* 129(5):1274–1281

29. Brodsky JB, Eggen M, Cannon WB (1993) Spontaneous pneumothorax in early pregnancy: successful management by thoracoscopy. *J Cardiothorac Vasc Anesth* 7(5):585–587
30. Bhatia P, Bhatia K (2000) Pregnancy and the lungs. *Postgrad Med J* 76(901):683–689
31. Gonano C, Pasquier J, Daccord C, Johnson SR, Harari S, Leclerc V, Falconer L, Miano E, Cordier JF, Cottin V et al (2018) Air travel and incidence of pneumothorax in lymphangioleiomyomatosis. *Orphanet J Rare Dis* 13(1):222
32. Taveira-DaSilva AM, Jones AM, Julien-Williams P, Yao J, Stylianou M, Moss J (2015) Severity and outcome of cystic lung disease in women with tuberous sclerosis complex. *Eur Respir J* 45(1):171–180
33. Cohen MM, Pollock-BarZiv S, Johnson SR (2005) Emerging clinical picture of lymphangioleiomyomatosis. *Thorax* 60(10):875–879
34. van Baal JG, Smits NJ, Keeman JN, Lindhout D, Verhoef S (1994) The evolution of renal angiomyolipomas in patients with tuberous sclerosis. *J Urol* 152(1):35–38
35. Avila NA, Dwyer AJ, Rabel A, Moss J (2007) Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. *Radiology* 242(1):277–285
36. Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA (2006) Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. *Kidney Int* 70(10):1777–1782
37. Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, Taveira-DaSilva AM, Johnson SR, Cottin V, Sahn SA et al (2017) Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline: *Am J Respir Crit Care Med* 196(10):1337–1348
38. Xu KF, Zhang P, Tian X, Ma A, Li X, Zhou J, Zeng N, Gui YS, Guo Z, Feng R et al (2013) The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). *Respir Med* 107(2):263–268
39. Hirose M, Matsumuro A, Arai T, Sugimoto C, Akira M, Kitaichi M, Young LR, McCormack FX, Inoue Y (2019) Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. *PLoS ONE* 14(2):e0212776
40. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J (2009) Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. *Chest* 135(5):1293–1300
41. Hayashi T, Kumasaka T, Mitani K, Okada Y, Kondo T, Date H, Chen F, Oto T, Miyoshi S, Shiraishi T et al (2016) Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses. *Hum Pathol* 50:34–42
42. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J (2004) Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. *Chest* 126(6):1867–1874
43. Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J (2010) The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. *Lymphat Res Biol* 8(1):9–19
44. Hayashida M, Yasuo M, Hanaoka M, Seyama K, Inoue Y, Tsumi K, Mishima M (2016) Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database. *Respir Investig* 54(3):193–200
45. Taveira-DaSilva AM, Johnson SR, Julien-Williams P, Johnson J, Stylianou M, Moss J (2020) Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts. *Thorax* 75(10):904–907
46. Koba T, Arai T, Kitaichi M, Kasai T, Hirose M, Tachibana K, Sugimoto C, Akira M, Hayashi S, Inoue Y (2018) Efficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: A report of 24 consecutive patients. *Respirology* 23(3):331–338
47. Kida Y (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *N Engl J Med* 365(3):271–272
48. Faehling M, Frohnmayer S, Leschke M, Trinajstic-Schulz B, Weber J, Liewald F (2011) Successful pregnancy complicated by persistent pneumothorax in a patient with lymphangioleiomyomatosis (LAM) on sirolimus. *Sarcoidosis Vasc Diffuse Lung Dis* 28(2):153–155
49. Faehling M, Wienhausen-Wilke V, Fallscheer S, Trinajstic-Schulz B, Weber J, Leschke M (2015) Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis (LAM). *Sarcoidosis Vasc Diffuse Lung Dis* 32(3):259–264
50. Sun R, Zhai R, Ma C, Miao W (2020) Combination of alogliquin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway. *Cancer Med* 9(3):1141–1151
51. Madhivanan K, Ramadesikan S, Hsieh WC, Aguilar MC, Hanna CB, Bacallao RL, Aguilar RC (2020) Lowe syndrome patient cells display mTOR- and RhoGTPase-dependent phenotypes alleviated by rapamycin and statins. *Hum Mol Genet* 29(10):1700–1715
52. Chang WY, Clements D, Johnson SR (2010) Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells. *Am J Physiol Lung Cell Mol Physiol* 299(3):L393–400
53. Yanagisawa S (2018) Treatment of Pulmonary Lymphangioleiomyomatosis during Pregnancy. *Am J Respir Crit Care Med* 197(11):1506–1507
54. Gupta N, Johnson SR, Moss J, McCormack FX (2018) Reply to Yanagisawa: Treatment of Pulmonary Lymphangioleiomyomatosis during Pregnancy. *Am J Respir Crit Care Med* 197(11):1507–1508
55. Agrawal A, Karle E, Patel TP, Wilson G, Hofmann H, Sunna R, Krvavac A (2020) A Pregnant Woman Presenting With Progressively Worsening Dyspnea and Pneumothorax. *Chest* 157(6):e193–e196
56. Wang Q, Luo M, Xiang B, Chen S, Ji Y (2020) The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis. *Respir Res* 21(1):55
57. Kaundinnyayana S, Kamath A (2022) Doxycycline use and adverse pregnancy or neonatal outcomes: A descriptive study using the United States Food and Drug Administration Adverse Event Reporting System database. *Health Sci Rep* 5(6):e931
58. Oprescu N, McCormack FX, Byrnes S, Kinder BW (2013) Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. *Lung* 191(1):35–42
59. Johnson J, Johnson SR (2019) Cross-sectional study of reversible airway obstruction in LAM: better evidence is needed for bronchodilator and inhaled steroid use. *Thorax* 74(10):999–1002
60. Le K, Steagall WK, Stylianou M, Pacheco-Rodriguez G, Darling TN, Vaughan M, Moss J (2018) Effect of beta-agonists on LAM progression and treatment. *Proc Natl Acad Sci U S A* 115(5):E944–e953
61. Kpodonu J, Massad MG, Chaer RA, Caines A, Evans A, Snow NJ, Geha AS (2005) The US experience with lung

- transplantation for pulmonary lymphangioliomyomatosis. *J Heart Lung Transplant* 24(9):1247–1253
62. Maurer JR, Ryu J, Beck G, Moss J, Lee JC, Finlay G, Brown K, Chapman J, McMahan J, Olson E et al (2007) Lung transplantation in the management of patients with lymphangioliomyomatosis: baseline data from the NHLBI LAM Registry. *J Heart Lung Transplant* 26(12):1293–1299
 63. Zhang J, Liu D, Yue B, Ban L, Zhou M, Wang H, Lv J, Wu B, Zhai Z, Xu KF et al (2021) A retrospective study of lung transplantation in patients with lymphangioliomyomatosis: challenges and outcomes. *Front Med (Lausanne)* 8:584826
 64. Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, Reynaud-Gaubert M, Boehler A, Brauner M, Popper H et al (2010) European Respiratory Society guidelines for the diagnosis and management of lymphangioliomyomatosis. *Eur Respir J* 35(1):14–26
 65. Wahedna I, Cooper S, Williams J, Paterson IC, Britton JR, Tattersfield AE (1994) Relation of pulmonary lymphangioliomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study. *Thorax* 49(9):910–914

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.